T cell broad betacoronavirus vaccine

EP4770669A2Pending Publication Date: 2026-07-08NEC ONCOIMMUNITY AS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
NEC ONCOIMMUNITY AS
Filing Date
2024-08-30
Publication Date
2026-07-08

AI Technical Summary

Technical Problem

Current vaccines for Betacoronaviruses, such as SARS-CoV-1 and SARS-CoV-2, primarily focus on inducing a humoral immune response through neutralizing antibodies, but they often fail to generate a robust cellular immune response, which is crucial for long-term immunity. Additionally, the high polymorphism of human leukocyte antigen (HLA) alleles complicates the development of vaccines that are effective across diverse HLA types.

Method used

The development of a vaccine composition that includes predicted cross-reactive Betacoronavirus epitopes capable of binding to a broad spectrum of HLA molecules. This composition comprises one or more epitope sequences with specific amino acid sequences, designed to stimulate a broad adaptive immune response, both cellular and humoral in nature, across the global human population.

Benefits of technology

The proposed vaccine composition has the potential to elicit a robust and sustained immune response, providing protection against multiple Betacoronavirus variants and covering a diverse spectrum of HLA types, thereby addressing the limitations of current vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024074380_06032025_PF_FP_ABST
    Figure EP2024074380_06032025_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.
Need to check novelty before this filing date? Find Prior Art